NL-OMON54321招募中3 期
Dose tapering and early discontinuation to increase cost-effectiveness of immunotherapy trial number 1 - Dedication-1 NVALT30
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 750
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Eligible for treatment of non-small cell lung cancer with pembrolizumab in line
- •with the current ESMO treatment guidelines
排除标准
- •Not willing to give informed consent
研究者
相似试验
招募中
3 期
Dose tapering and Early Discontinuation to InCreAse cosT-effictIveness Of immunotherapy for Non-small cell lung carcinoma trial number 1 (NVALT-30 - Dedication-1)2024-516195-15-00Stichting Radboud universitair medisch centrum750
进行中（未招募）
1 期
Dose reduction and withdrawal of biological therapy in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: Protocol for a 18 months multi-centre trialEUCTR2017-001970-41-DKMD, PhD Salome Kristensen180
招募中
不适用
ong-term beta-blocker therapy after acute myocardial infarctioDiseases of the circulatory systemKCT0005903Samsung Medical Center2,500
已完成
2 期
De-escalation and stopping treatment of imatinib, nilotinib or sprycel in chronic myeloid leukaemiaTopic: National Cancer Research NetworkSubtopic: Haematological OncologyDisease: Leukaemia (chronic)Chronic myelogenous leukaemiaCancerISRCTN74084226niversity of Liverpool (UK)168
进行中（未招募）
1 期
A trial of de-escalation and stopping treatment in chronic myeloid leukaemia patients with excellent responses to tyrosine kinase inhibitor therapy DESTINY (De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in chronic myeloid leukaemia)Chronic myeloid leukaemiaMedDRA version: 16.0 Level: LLT Classification code 10009015 Term: Chronic myeloid leukemia System Organ Class: 100000004864MedDRA version: 16.0 Level: LLT Classification code 10009016 Term: Chronic myeloid leukemia in remission System Organ Class: 100000004864EUCTR2012-004025-24-GBniversity of Liverpool174